First U.S. Pilot of Sensara Proves Successful for RiverWoods Exeter Residents - RiverWoods Retirement Community

First U.S. Pilot of Sensara Proves Successful for RiverWoods Exeter Residents

RiverWoods_Exeter_CCRC_NH_Sesara
The three-month pilot study was conducted with the goal of improving the quality of life, safety, and privacy for residents of RiverWoods Exeter.

Sensor Technology Increases Resident Confidence and Reduces Falls

PRESS RELEASE – For Immediate Release

Exeter, NH—August 21, 2019— RiverWoods Continuing Care Retirement Community recently completed a successful three-month pilot study that integrated new technology to improve the quality of life, safety, and privacy for residents at The Boulders, newest of its three campuses.

According to Linda Thurston, Director of Health Services at RiverWoods Exeter, measures for success included reduction in falls, enhanced privacy for residents and decrease in sleep disturbance. Additionally, eight out of nine residents felt Sensara has increased their sense of privacy and 100% of caregivers say it is easy to learn.

“This study also improved workflow for staff, which enabled caregivers to spend more time with our residents,” she said. “This study has been incredibly valuable for us.”

The technology tested in the study was developed by Dutch company Sensara, a spin-off from the Dutch Scientific Institute, which began researching how to support senior citizens with smart sensor technology fifteen years ago.

“This was Sensara’s first U.S. experience,” added Thurston. “We were honored to partner with them and look forward to continuing to use their technology to enhance the lives of our residents in measurable ways.”

RiverWoods Exeter is an award-winning, accredited non-profit Continuing Care Retirement Community (CCRC) that provides several levels of living: Independent, Assisted Living, Memory Support, and Skilled Nursing.

To learn more about the partnership between RiverWoods Exeter and Sensara, contact  Paul Ruijgt, business development director, at [email protected] or (978) 847 4772.

For more information about the pilot study click here .